Merck, 94101451-1VL, AT-3.1

Application
Carcinogenesis studies, cytogenetic analysis.
Biochem/physiol Actions
AT-3.1 is a subclone of the AT-3 cell line being one of a series of related variants originating from a single spontaneous adenocarcinoma in the dorsal lobe of the prostate of an aged male inbred Copenhagen rat. AT-3.1 was derived from an anaplastic tumour with a high rate of metastases and is androgen-independent.
Rat dorsal prostatic adenocarcinoma
Preparation Note
RPMI 1640 + 2mM Glutamine + 250nM Dexamethasone (DXMT) + 10% Foetal Bovine Serum (FBS).
Split sub-confluent cultures (70-80%) 1:10 to 1:20 i.e. seeding at 2-4 x10,000 cells/cm² using 0.25% trypsin/EDTA; 5% CO₂; 37°C.
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to [email protected].